Ownership and insider activity for Aura Biosciences, Inc. (AURA): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Headquartered in Cambridge, Massachusetts, Aura Biosciences, Inc. is a biotechnology firm established in 2009 that specializes in pioneering cancer treatments. The company leverages its proprietary virus-like drug conjugate (VDC) technology platform to address tumors with significant unmet medical needs, specifically in ocular (eye) and urologic oncology.
Price
| Price | $6.73 |
| Market Cap | $696M |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-09-01 | Person Julie | A-Award | 212,389 | $1.6M |
| 2026-09-01 | Person Julie | A-Award | 107,611 | |
| 2026-09-01 | Kratz Erica | A-Award | 199,115 | $1.5M |
| 2026-09-01 | Kratz Erica | A-Award | 100,885 | |
| 2026-09-01 | Hopkins Janet Jill | A-Award | 58,850 | |
| 2026-09-01 | Hopkins Janet Jill | A-Award | 116,150 | $863K |
| 2026-09-01 | Elazzouzi Amy | A-Award | 23,540 | |
| 2026-09-01 | Elazzouzi Amy | A-Award | 46,460 | $345K |
| 2026-09-01 | Abu-Absi Susan | A-Award | 265,487 | $2.0M |
| 2026-09-01 | Abu-Absi Susan | A-Award | 134,513 |
Balance Sheet (10y)
| Year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $32.5M | $17.4M | $149.1M | $121.6M | $41.1M | $31.7M | $59.5M |
| Short-term Investments | 0 | 0 | 0 | $67.2M | $185.1M | $119.4M | $84.7M |
| Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $33.3M | $18.5M | $153.7M | $196.7M | $231.8M | $160.6M | $149.7M |
| Property, Plant & Equipment | $3.6M | $3.6M | $6.2M | $26.0M | $22.0M | $20.6M | $18.5M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $37.1M | $22.1M | $160.0M | $223.9M | $255.1M | $182.5M | $169.4M |
| Accounts Payable | $2.3M | $611000 | $2.4M | $2.9M | $1.8M | $2.3M | $1.5M |
| Short-term Debt | 0 | $15000 | 0 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | $6.1M | $2.7M | $7.4M | $10.5M | $12.4M | $14.9M | $18.4M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | $14.1M |
| Total Liabilities | $6.3M | $2.7M | $7.7M | $28.4M | $29.2M | $30.5M | $32.5M |
| Retained Earnings | -$94.7M | -$116.9M | -$152.1M | -$210.9M | -$287.3M | -$374.2M | -$480.4M |
| Total Equity | $30.8M | $19.4M | $152.3M | $195.6M | $225.8M | $152.0M | $136.9M |
| Total Debt | $49000 | $15000 | $975000 | $20.9M | $19.6M | $18.8M | $17.4M |
| Net Debt | -$32.4M | -$17.4M | -$148.1M | -$168.0M | -$206.6M | -$132.3M | -$126.9M |
| Working Capital | $27.2M | $15.8M | $146.3M | $186.2M | $219.4M | $145.7M | $131.4M |
Financial Health
| Debt / Equity | 0.05 |
| Current Ratio | 16.82 |
| Piotroski F-Score | 1 |
| Altman Z-Score | 0.83 |
Profitability
| Return on Equity | -73.18% |
| Return on Invested Capital | -41.61% |
| Return on Assets | -37.63% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ALT · ANNX · DBVT · DSGN · ENGN · KRRO · LBRX
Explore sector: Healthcare · Biotechnology
More sections of AURA: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks